Sammy Saab, a professor of medicine and surgery at UCLA and a paid consultant to Gilead Sciences, writes this article defending the high price of Gilead Sciences’ Sovaldi. Pointing to the Decrease in treatment time, Decreased overall expense of disease, and Increased success rate, Saab explains why it is difficult for him to understand how Sovaldi has come under such disproportionate criticism. Read more here. (Source: Sammy Saab, USA TODAY, 7/16/14).
You are here: / / Sovaldi Worth The Price – Not The Controversy